REPORT ID 2833

China Antidiabetic Thiazolidinediones Market Research Report 2017

Publish Date
11-Dec-17
Pages
99
Format
Electronic (PDF)

The global Antidiabetic Thiazolidinediones market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Antidiabetic Thiazolidinediones development status and future trend in China, focuses on top players in China, also splits Antidiabetic Thiazolidinediones by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include
    Sanofi
    Takeda Pharmaceuticals
    Eli Lilly
    Merck & Co.
    Novo Nordisk
    Bristol-Myers Squibb
    Pfizer
    AstraZeneca
    GlaxoSmithKline
    Boehringer Ingelheim

Geographically, this report splits the China market into six regions,
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
    Rosiglitazone
    Pioglitazone

On the basis of the end users/application, this report covers
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

China Antidiabetic Thiazolidinediones Market Research Report 2017
1 Antidiabetic Thiazolidinediones Overview
    1.1 Product Overview and Scope of Antidiabetic Thiazolidinediones
    1.2 Classification of Antidiabetic Thiazolidinediones by Product Category
        1.2.1 China Antidiabetic Thiazolidinediones Sales (K Pcs) Comparison by Type (2012-2022)
        1.2.2 China Antidiabetic Thiazolidinediones Sales (K Pcs) Market Share by Type in 2016
        1.2.3 Rosiglitazone
        1.2.4 Pioglitazone
    1.3 China Antidiabetic Thiazolidinediones Market by Application/End Users
        1.3.1 China Antidiabetic Thiazolidinediones Sales (K Pcs) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 China Antidiabetic Thiazolidinediones Market by Region
        1.4.1 China Antidiabetic Thiazolidinediones Market Size (Million USD) Comparison by Region (2012-2022)
        1.4.2 South China Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.3 East China Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.4 Southwest China Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.5 Northeast China Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.6 North China Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
        1.4.7 Central China Antidiabetic Thiazolidinediones Status and Prospect (2012-2022)
    1.5 China Market Size (Sales and Revenue) of Antidiabetic Thiazolidinediones (2012-2022)
        1.5.1 China Antidiabetic Thiazolidinediones Sales (K Pcs) and Growth Rate (%)(2012-2022)
        1.5.2 China Antidiabetic Thiazolidinediones Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 China Antidiabetic Thiazolidinediones Market Competition by Players/Manufacturers
    2.1 China Antidiabetic Thiazolidinediones Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2 China Antidiabetic Thiazolidinediones Revenue and Share by Players/Manufacturers (2012-2017)
    2.3 China Antidiabetic Thiazolidinediones Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.4 China Antidiabetic Thiazolidinediones Market Competitive Situation and Trends
        2.4.1 China Antidiabetic Thiazolidinediones Market Concentration Rate
        2.4.2 China Antidiabetic Thiazolidinediones Market Share of Top 3 and Top 5 Players/Manufacturers
        2.4.3 Mergers & Acquisitions, Expansion in China Market
    2.5 China Players/Manufacturers Antidiabetic Thiazolidinediones Manufacturing Base Distribution, Sales Area, Product Types

3 China Antidiabetic Thiazolidinediones Sales and Revenue by Region (2012-2017)
    3.1 China Antidiabetic Thiazolidinediones Sales (K Pcs) and Market Share by Region (2012-2017)
    3.2 China Antidiabetic Thiazolidinediones Revenue (Million USD) and Market Share by Region (2012-2017)
    3.3 China Antidiabetic Thiazolidinediones Price (USD/Pcs) by Regions (2012-2017)

4 China "&B1&" Sales and Revenue by Type/ Product Category (2012-2017)"
    4.1 China Antidiabetic Thiazolidinediones Sales (K Pcs) and Market Share by Type/ Product Category (2012-2017)
    4.2 China Antidiabetic Thiazolidinediones Revenue (Million USD) and Market Share by Type (2012-2017)
    4.3 China Antidiabetic Thiazolidinediones Price (USD/Pcs) by Type (2012-2017)
    4.4 China Antidiabetic Thiazolidinediones Sales Growth Rate (%) by Type (2012-2017)

5 China "&B1&" Sales by Application (2012-2017)"
    5.1 China Antidiabetic Thiazolidinediones Sales (K Pcs) and Market Share by Application (2012-2017)
    5.2 China Antidiabetic Thiazolidinediones Sales Growth Rate (%) by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6 China Antidiabetic Thiazolidinediones Players/Suppliers Profiles and Sales Data
    6.1 Sanofi
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Sanofi Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Takeda Pharmaceuticals
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Eli Lilly
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Merck & Co.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Novo Nordisk
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Bristol-Myers Squibb
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Pfizer
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Pfizer Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 AstraZeneca
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 GlaxoSmithKline
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Boehringer Ingelheim
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Antidiabetic Thiazolidinediones Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.10.4 Main Business/Business Overview

7 Antidiabetic Thiazolidinediones Manufacturing Cost Analysis
    7.1 Antidiabetic Thiazolidinediones Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Antidiabetic Thiazolidinediones

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Antidiabetic Thiazolidinediones Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Antidiabetic Thiazolidinediones Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 China Antidiabetic Thiazolidinediones Market Size (Sales and Revenue) Forecast (2017-2022)
    11.1 China Antidiabetic Thiazolidinediones Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    11.2 China Antidiabetic Thiazolidinediones Sales (K Pcs) Forecast by Type (2017-2022)
    11.3 China Antidiabetic Thiazolidinediones Sales (K Pcs) Forecast by Application (2017-2022)
    11.4 China Antidiabetic Thiazolidinediones Sales (K Pcs) Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List